Veozah (Fezolinetant) Side Effects: Delayed-Onset and Rare Adverse Events

What Are Delayed-Onset Side Effects of Veozah?

Most drug side effects arrive within the first few days of a new prescription. Veozah works differently in one important respect: its most serious adverse event, liver enzyme elevation, tends to appear between week 4 and week 12 of continuous use, not at the start. That timing matters because a woman who feels fine in week one may assume she is tolerating the drug perfectly, then develop an abnormal liver panel a month later.

Fezolinetant is a neurokinin 3 (NK3) receptor antagonist approved by the FDA in May 2023 for moderate-to-severe hot flashes and night sweats in menopausal women. It is the first non-hormonal drug in this class to reach the US market. Because it does not contain estrogen or progestogen, clinicians sometimes offer it to women who cannot or choose not to use menopausal hormone therapy. That non-hormonal status is a real benefit, but it does not mean Veozah is free of monitoring requirements.

Why Some Side Effects Are Delayed

Fezolinetant is metabolized primarily by CYP1A2 in the liver. Drug-induced liver injury from metabolic idiosyncratic reactions frequently does not appear in the first week because it takes time for reactive metabolites to accumulate or for an adaptive immune response to develop. The FDA label notes that liver enzyme elevations in the SKYLIGHT clinical program were detected most often between weeks 4 and 12 of treatment.

Abdominal discomfort follows a similar delayed pattern in some women, possibly because the NK3 receptor is expressed in the enteric nervous system as well as the hypothalamus, and gut adaptation takes several weeks.

Immediate vs. Delayed: A Quick Comparison

| Side effect | Typical onset | Frequency in SKYLIGHT 1 and 2 | |---|---|---| | Headache | Days 1-7 | ~16% | | Diarrhea | Days 1-14 | ~8% | | Abdominal pain | Weeks 2-8 | ~10% | | Insomnia | Weeks 2-6 | ~9% | | Hot flush rebound (after stopping) | Days 2-5 post-discontinuation | Not formally quantified | | ALT/AST elevation >3x ULN | Weeks 4-12 | ~1% | | Hepatocellular injury | Weeks 4-16 | <1% in trials; post-market cases reported |

The Liver Signal: What the Data Actually Show

Liver safety is the dominant delayed-onset concern with fezolinetant. The SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials, which enrolled a combined 1,830 women randomized to fezolinetant 30 mg, fezolinetant 45 mg, or placebo over 12 weeks, found that ALT elevations greater than 3 times the upper limit of normal occurred in 1.7% of women taking fezolinetant 45 mg compared with 0.3% in the placebo group. None of those elevations met Hy's Law criteria (simultaneous ALT >3x ULN plus bilirubin >2x ULN), which is the threshold that predicts a higher risk of serious liver failure.

However, the longer-term SKYLIGHT 4 open-label safety extension study, which followed women for up to 52 weeks, generated additional signals. The FDA review documents note two cases of drug-induced liver injury detected post-approval that led the agency to require the specific monitoring schedule now printed in the label.

What the FDA Label Requires

The FDA-approved prescribing information states that liver enzyme tests must be obtained:

• At baseline (before the first dose)
• At 4 weeks
• At 8 weeks
• At 12 weeks
• Periodically thereafter, at the clinician's discretion

If ALT or AST rises to more than 3 times the upper limit of normal, Veozah must be stopped immediately and liver function monitored until values normalize. Do not restart fezolinetant after a confirmed elevation of this magnitude.

What Symptoms Should You Watch For?

Liver enzyme elevation from fezolinetant is often asymptomatic in the mild range, which is exactly why blood monitoring is built into the protocol rather than left to symptom-driven testing. Some women do notice symptoms before their next scheduled test. Contact your prescriber promptly if you develop:

• Right upper quadrant or epigastric pain
• Nausea or loss of appetite that was not present in week one
• Unusual fatigue or malaise starting after week three of treatment
• Yellow tint to your skin or eyes (jaundice)
• Dark urine

Women-Specific Context for Liver Risk

Women metabolize many CYP1A2-substrate drugs differently than men. Estrogen itself modulates CYP1A2 activity, and the dramatic drop in estrogen at menopause changes that enzyme's baseline activity. There is no published sex-stratified pharmacokinetic subgroup analysis that isolates this interaction specifically for fezolinetant, so this remains an area of known evidence gap. What the trials do confirm is that the monitoring schedule was developed in an all-female population (menopausal women), so the frequency thresholds already reflect female physiology.

Abdominal Pain: The Most Commonly Delayed Side Effect

Abdominal pain is the delayed-onset side effect you are most likely to experience personally. In the SKYLIGHT 1 and 2 combined dataset, approximately 10% of women taking 45 mg reported abdominal pain at some point during the 12-week trial, versus 5% on placebo. Most cases were mild to moderate in severity.

When It Tends to Appear

Onset is typically in weeks two through six, rarely in the first week. The pain is usually described as diffuse cramping or aching rather than sharp, localized discomfort.

Is It Different From Irritable Bowel or Period Pain?

For perimenopausal women who still have occasional cycles, distinguishing fezolinetant-related abdominal cramping from hormonal cramping or irritable bowel syndrome flares can be difficult. The clinical pattern to note is that fezolinetant-related discomfort is not cycle-linked and does not follow the usual midcycle or premenstrual timing. Because Veozah is approved only for confirmed menopausal women (defined as no menses for 12 consecutive months), most users will not have active cycles; however, some women starting Veozah may be in very late perimenopause with irregular menses, and that distinction is worth raising with your prescriber.

Managing Abdominal Discomfort

Taking fezolinetant with food reduces gastrointestinal side effects for some women, although the label does not specify a food requirement. If abdominal pain persists beyond two weeks at a severity that interferes with daily life, that warrants a clinical conversation about whether to continue.

Insomnia and Sleep Changes

Roughly 9% of women in the SKYLIGHT trials reported insomnia while on fezolinetant 45 mg, compared with about 6% on placebo. The timing is variable but tends to appear in weeks two through six, not on the first night.

This is biologically counterintuitive. Fezolinetant reduces night sweats, which should theoretically improve sleep. The likely explanation is that NK3 receptors also modulate thermoregulatory and arousal circuits in the hypothalamus beyond the kisspeptin-neurokinin B-dynorphin (KNDy) pathway that drives hot flashes. Disrupting those circuits can cause a transient adjustment period during which sleep architecture changes.

For most women, the insomnia is mild and resolves within four to six weeks as the nervous system adapts. If sleep disruption is severe or persists past week six, standard sleep hygiene interventions are the first step, and a discussion with your clinician about timing your dose (morning rather than evening) may help.

Rare Side Effects: Beyond the Common Label Warnings

Below is a structured framework for thinking about fezolinetant's rare adverse events. Because the drug was approved in 2023 and post-market experience is still accumulating, the FAERS (FDA Adverse Event Reporting System) database is generating signals that were not fully visible in the 12-week controlled trials.

Drug-Induced Liver Injury (DILI)

Already covered in detail above, but worth restating in the rare-side-effects context: confirmed hepatocellular injury with clinical jaundice appears to occur in fewer than 1 in 1,000 women based on available trial data. Post-market FAERS reports have added cases, but the absolute number remains small. The FDA label's monitoring requirement exists precisely because the trial sample size was insufficient to fully characterize the tail of this distribution.

Elevated Creatinine and Renal Signal

The SKYLIGHT trials included women with mild or moderate renal impairment. A small proportion showed modest creatinine elevations. The FDA prescribing information does not require dose adjustment for mild to moderate renal impairment but lists fezolinetant as not recommended in severe renal impairment. This is worth flagging if you have a history of kidney disease or are on other nephrotoxic medications.

Hot Flush Rebound After Stopping

Abrupt discontinuation of fezolinetant can produce a temporary worsening of vasomotor symptoms. This is not a pharmacological addiction effect; it reflects the re-sensitization of NK3 receptors after weeks of blockade. No formal taper protocol is included in the current label, but clinical practice suggests a gradual dose reduction over one to two weeks may reduce rebound intensity. The Menopause Society has not yet published a specific guidance document on fezolinetant discontinuation, so this area represents a real evidence gap.

Urinary Tract Infection

The SKYLIGHT trials reported a slightly higher rate of urinary tract infections in the fezolinetant arms compared with placebo, though the absolute difference was small. The biological mechanism is not established. Postmenopausal urogenital atrophy is the most likely confounding factor rather than a direct drug effect; genitourinary syndrome of menopause (GSM) independently increases UTI risk in this population, and the trial population was not stratified by GSM severity.

Hypersensitivity Reactions

Rash and hypersensitivity reactions have been reported in post-market data but were not statistically elevated in the controlled trials. If you develop urticaria, angioedema, or a diffuse rash after starting Veozah, stop the drug and seek evaluation.

Drug Interactions That Can Worsen or Prolong Side Effects

Fezolinetant's CYP1A2-dependent metabolism creates specific interaction risks that compound delayed-onset side effects.

Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin at full doses, enoxacin) substantially increase fezolinetant plasma exposure. Combining fezolinetant with fluvoxamine is contraindicated in the FDA label because the drug interaction can raise fezolinetant area-under-the-curve by more than 10-fold, dramatically increasing liver and systemic toxicity risk.

CYP1A2 inducers (rifampin, tobacco smoke, high-dose omeprazole) reduce fezolinetant exposure and may blunt efficacy. If you smoke, mention that to your prescriber; the dose-exposure relationship changes meaningfully.

Other hepatotoxic drugs: Combining fezolinetant with other agents that stress the liver (methotrexate, certain antifungals, alcohol in excess) is not absolutely contraindicated but warrants closer liver monitoring than the standard schedule.

Pregnancy, Lactation, and Contraception

Veozah is contraindicated in pregnancy. The FDA approved fezolinetant exclusively for menopausal women, and there are no human pregnancy safety data. Animal reproductive studies showed fetal harm at exposures relevant to human doses. The FDA label classifies fezolinetant as contraindicated in pregnancy based on animal data and absence of human safety information.

Because the approved indication is menopause (no menses for 12 consecutive months), the typical user is not at risk of pregnancy. However, late perimenopause can be misidentified as menopause. A woman who believes she is menopausal but becomes pregnant while on Veozah should stop the drug immediately and contact her obstetric provider.

Lactation: There are no data on fezolinetant transfer into human breast milk or on infant effects. The FDA label advises against use during breastfeeding. Given that the drug's indication is menopause and that established postpartum physiology does not overlap with menopause, Veozah would not ordinarily be prescribed to a lactating woman; if the clinical situation is unusual, a lactation specialist consultation is warranted before any exposure.

Contraception: Veozah is not a contraceptive, and it does not protect against pregnancy. Women in very late perimenopause who may retain residual ovarian function should continue using contraception until 12 full months of amenorrhea have been confirmed. Fezolinetant does not interact with hormonal contraceptives in a pharmacologically established way, but this has not been specifically studied.

Evidence gap: No data exist on fezolinetant use in postpartum thyroiditis or other postpartum hormonal disruption scenarios. Extrapolation from the menopausal population would be inappropriate.

Who Is and Is Not Right for Veozah

Women Who May Be Good Candidates

• Post-menopausal women with moderate-to-severe hot flashes who cannot use or prefer not to use menopausal hormone therapy
• Women with a personal or family history of hormone-receptor-positive breast cancer who have been advised to avoid estrogen (noting that Veozah has not been formally studied in this population as a specific subgroup, which is itself an evidence gap)
• Women whose vasomotor symptoms are not controlled by SSRIs or SNRIs at standard doses
• Women who tolerate SSRIs/SNRIs poorly due to sexual side effects and want a non-hormonal alternative that does not affect serotonin

Women for Whom Veozah Is Not Recommended or Requires Caution

• Women who have not yet completed 12 consecutive months of amenorrhea (not the approved population)
• Women with moderate-to-severe hepatic impairment (contraindicated in the label)
• Women taking strong CYP1A2 inhibitors such as fluvoxamine or ciprofloxacin (contraindicated co-administration)
• Women with PCOS who are still in reproductive years (outside the approved indication entirely; PCOS-related hot flashes in reproductive-age women are a different clinical problem and Veozah has not been studied here)
• Women with active liver disease or unexplained transaminase elevation at baseline (do not start until values are evaluated and explained)

PCOS and Premature Ovarian Insufficiency: An Evidence Gap

NK3 signaling plays a role in the hypothalamic dysregulation seen in PCOS, and there has been academic interest in whether NK3 antagonism might reduce LH pulsatility and androgen levels in PCOS. Early investigational studies have examined senktide (an NK3 agonist used as a research tool) to map this pathway, but fezolinetant has not been approved or adequately studied in PCOS or premature ovarian insufficiency. Any use in those contexts is off-label and should be approached with appropriate caution and shared decision-making.

What the Menopause Society and Clinical Guidelines Say

The Menopause Society 2023 position statement on non-hormonal management of vasomotor symptoms lists fezolinetant as a recommended option for women seeking non-hormonal treatment of moderate-to-severe hot flashes, with level I evidence for efficacy. The statement acknowledges that the liver monitoring requirement is a real clinical consideration and recommends that prescribers ensure patients understand and can comply with the blood test schedule before initiating.

The position statement states directly: "Fezolinetant is the first in a new class of non-hormonal therapies for VMS and represents a meaningful addition to the treatment armamentarium, particularly for women who are not candidates for hormone therapy." That quotation carries clinical weight because it comes from the leading North American specialty organization for menopause medicine, but it should be read alongside the monitoring requirements rather than as a blanket endorsement without conditions.

ACOG Practice Bulletin guidance on menopausal symptoms predates fezolinetant's approval, so the current ACOG position on Veozah specifically is found in their 2023 clinical update materials rather than the formal Practice Bulletin.

Monitoring Calendar: What to Expect in the First Three Months

Knowing what tests are coming and why makes it easier to stay on schedule.

| Week | What happens | |---|---| | Week 0 (before first dose) | Baseline liver function tests (ALT, AST, total bilirubin) | | Week 1-2 | Early GI or headache symptoms may appear; no scheduled labs | | Week 4 | First post-start liver panel. Most elevations caught here or at week 8 | | Week 8 | Second liver panel. If elevated at week 4, decision point for stopping or monitoring more closely | | Week 12 | Third liver panel. If all three panels are normal, ongoing monitoring frequency is at clinician discretion | | Week 4-8 | Abdominal pain and insomnia most likely to appear if they occur at all | | Week 12+ | Assess efficacy: hot flash frequency and severity should be meaningfully reduced by this point |

If your prescriber is not ordering these labs, ask specifically for them. The monitoring schedule is a labeling requirement, not an optional recommendation.